SUPN Q4 2020 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q4 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$144M+42.9% YoY

Gross Profit

$125M87.1% margin

Operating Income

$43M30.0% margin

Net Income

$31M21.4% margin

EPS (Diluted)

$0.57

QoQ Revenue Growth

-7.5%

Cash Flow

Operating Cash Flow

$32M

Free Cash Flow

$32M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$759M

Stockholders' Equity

$745M

Cash & Equivalents

$289M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$144M	$100M	+42.9%
Gross Profit	$125M	$96M	+29.8%
Operating Income	$43M	$41M	+5.3%
Net Income	$31M	$33M	-7.1%

Revenue Segments

Product

$141M50%

Trokendi Xr

$79M28%

APOKYN

$31M11%

Oxtellar X R

$23M8%

MYOBLOC

$4M2%

XADAGO

$4M1%

Royalty

$3M1%